ZME Science on MSN13m
Could CAR-T Therapy Be the End of Lifelong Lupus Medication? Early Results Say ‘Yes’T-cells are real life saviors. If modified properly, they can save lupus patients from the trouble of taking medicines ...
Most cancer treatments—from chemotherapies to engineered immune cells—have a host of side effects, in large part because they ...
Researchers advance CAR T cell therapy for solid tumors by innovating ways to overcome the unique barriers of solid tumor ...
GlobalData on MSN8h
BioNTech signs agreement to acquire BiotheusBioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...
Hosted on MSN23d
New CAR-T cells offer on-demand control for cancer treatmentLudwig Cancer Research scientists have devised new types of chimeric antigen-receptor (CAR) T cells—a type of cancer ...
These findings suggest that KIR2DS2-positive (KIR2DS2+) natural killer (NK) cells could be an attractive therapeutic target ...
MedPage Today on MSN6d
Overcoming the Challenges of Applying CAR T-Cell Therapy to Solid TumorsOpens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window ...
A recent meta-analysis investigating cardiovascular complications in adults undergoing chimeric antigen receptor (CAR) T-cell ...
PHILADELPHIA, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Interius BioTherapeutics, a clinical-stage company engineering targeted, programmable vectors for the precision delivery of genetic medicines, today ...
INT2104 is a novel in vivo chimeric antigen receptor (CAR) gene therapy designed to generate CAR-T and CAR-NK cells in the patient’s body to target CD20-expressing malignant B cells Interim ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback